biOasis Technologies Inc.
TSX VENTURE : BTI

biOasis Technologies Inc.

February 15, 2012 10:10 ET

biOasis Named to TSX Venture Top 50®

VANCOUVER, BRITISH COLUMBIA--(Marketwire - Feb. 15, 2012) - biOasis Technologies Inc. (TSX VENTURE:BTI) announces it has been named one of the 2012 TSX Venture Top 50® companies. The TSX Venture 50® includes the top 10 companies in 5 major industry sectors that have been identified as leaders in providing shareholder value on Canada's junior stock exchange.

"We are very proud to be recognized as one of the top performing companies by being named to the 2012 TSX Venture Top 50®," says Rob Hutchison. "We believe this is a strong testament to our biOasis staff, management and directors and we could not have achieved this without our loyal shareholder base and we look forward to an exciting year ahead."

About the TSX Venture Top 50®

The TSX Venture 50® are the top 10 companies listed on the TSX Venture Exchange, in each of five major industry sectors - mining, oil & gas, technology & life sciences, diversified industries and clean technology - based on a ranking formula with equal weighting given to return on investment, market cap growth, trading volume and analyst coverage. All data was as of December 31, 2011.

ABOUT BIOASIS

biOasis Technologies Inc. is a biopharmaceutical company headquartered in Vancouver, Canada. Based on Transcend, biOasis's proprietary brain delivery platform, the Company is focused on creating new drugs that can cross the blood-brain barrier to address unmet medical needs in the treatment of brain diseases such as neurodegeneration, metastatic cancer and metabolic diseases. biOasis trades on the TSX Venture Exchange under the symbol "BTI". For more information about the Company please visit www.bioasis.ca.

On Behalf of the Board of Directors

Rob Hutchison, Chairman & CEO

"Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release."

Contact Information